Showing results (141-150 of 160) with videos related to
Sort By:
Pageof 16
International Journal of Radiation Oncology, Biology, Physics|April 21, 2021
Association of Epigenetic Age Acceleration With Risk Factors, Survival, and Quality of Life in Patients With Head and Neck CancerCanhua Xiao, Andrew H Miller, Gang Peng, et al.Journal of the National Cancer Institute|September 2, 2022
Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell CarcinomaCristina P Rodriguez, Hyunseok Kang, Jessica L Geiger, et al.Dermatology and Therapy|November 9, 2023
Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629Åse Bratland, Eva Munoz-Couselo, Laurent Mortier, et al.JCO Oncology Advances|April 2, 2026
Functional impact of transoral surgery and risk-based adjuvant therapy in human papillomavirus-associated oropharyngeal cancer: swallowing outcomes from ECOG-ACRIN E3311Katherine A Hutcheson, Yael Flamand, Beatrice Manduchi, et al.European Journal of Cancer (Oxford, England : 1990)|January 31, 2024
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patientsJulie R Brahmer, Georgina V Long, Omid Hamid, et al.Cancer|March 13, 2026
A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950)Aarti Bhatia, Zhengjia Chen, Yuji Zhang, et al.JAMA Oncology|June 14, 2019
Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical TrialBarbara Burtness, Robert Haddad, José Dinis, et al.The Lancet. Oncology|April 1, 2024
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trialJean-Pascal Machiels, Yungan Tao, Lisa Licitra, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2026
Amivantamab in recurrent/metastatic HNSCC after checkpoint inhibitor and chemotherapy: pivotal results from the phase 1b/2 OrigAMI-4 studyBarbara Burtness, Ari J Rosenberg, Benoit Calderon, et al.Lancet (London, England)|November 20, 2018
Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trialMaura L Gillison, Andy M Trotti, Jonathan Harris, et al.Pageof 16